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Abstract

Acute HIV infection (AHI) is accompanied by central nervous system infection and
immune activation. We investigated baseline predictors of neuropsychological (NP)
performance in Thai participants with AHI and the effect of antiretroviral therapy (ART)
on domains of functioning known to be affected by HIV.

36 participants with AHI (89% male, median age of 28 years, median time since HIV
exposure of 19 days) were evaluated at baseline and 3 and 6 months after ART.
Performance on the Grooved Pegboard test (GP), Color Trails 1 & 2 (CT1, CT2), and
Trails Making Test A (TM) were standardized to 251 age and education matched HIVuninfected Thais and summarized as a composite score (NPZ-4). Change in NP
performance from baseline to 6 months was compared between AHI participants and
matched Thai HIV- controls (n=45, 51% male, median age of 36 years) to account for
practice effects. Analyses included Spearman correlation, multivariable regression, nonparametric repeated measures ANOVA, and Mann-Whitney U test.

Baseline NP scores for the AHI group were similar to controls on each test (z scores
range: -0.26 to -0.13). NP performance was negatively correlated with cerebrospinal fluid
(CSF) HIV RNA (r = -0.493, p = 0.023) and days post-transmission (r = -0.389, p =
0.019). NP performance improved on CT1, CT2, and TM in the initial 3 months (ps
<0.01) with no significant change during the last 3 months. Only improvement in CT1
was greater than that seen in controls at 6 months (p=0.018). Eight participants performed

>1 standard deviation below normative means on >2 NP tests at baseline. This subgroup
had higher cerebrospinal fluid (CSF) HIV RNA compared to the rest of the AHI group
(p=0.047) and exhibited no improvement in NP performance across the follow-up
periods.

Most AHI individuals had normal NP performance and early ART slightly improved their
psychomotor function. However, approximately 25% of AHI individuals had impaired
NP performance which correlated with higher CSF HIV RNA, and these abnormalities
were not reversed by early short-term ART possibly indicating limited reversibility of
cognitive impairment in a subset of AHI individuals.
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INTRODUCTION
Clinical features of HIV-associated neurocognitive disorders (HAND)
HIV infection is associated with a wide range of central and peripheral neurological
complications. These include focal central nervous system (CNS) disorders such as
cerebral

toxoplasmosis,

primary

CNS

lymphoma,

and

progressive

multifocal

leukoencephalopathy (PML), and non-focal disorders such as encephalitis, metabolic and
toxic encephalopathies, peripheral neuropathy, and neurocognitive disease [1, 2]. The
spectrum of neurocognitive disease currently documented in the HIV-infected population
spans cognitive, motor, and behavioral impairments and is termed “HIV-associated
neurocognitive disorders” (HAND) [3]. It ranges from asymptomatic neurocognitive
impairment (ANI), to minor neurocognitive disorder (MND) and HIV-associated
dementia (HAD) [3]. Patients with ANI have impairment in at least 2 cognitive areas,
which do not interfere with daily functioning. The cognitive domains tested include
attention/memory, learning, executive function, processing speed, and motor skills.
Patients with MND similarly have cognitive impairment in 2 or more domains; but in
addition, they suffer from mild functional impairment. Lastly, patients with HAD exhibit
marked cognitive impairment in 2 or more domains, with marked functional impairment
[4].

Despite access to antiretroviral therapy (ART), a large percentage of chronically infected
HIV-positive individuals still exhibit mild forms of HAND [5, 6]. Prior to widespread
use of ART, 15-20% of HIV patients developed HAD [4]; but that incidence is now
greatly reduced. In contrast, the prevalence estimates of milder forms of cognitive
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impairment (ANI and MND) have not decreased, with up to 50% of chronically infected
HIV-positive individuals still manifesting some degree of cognitive dysfunction [5-8].
While the frequency and magnitude of cognitive deficits in HIV-infected individuals with
established infection have been well documented, limited information is available
regarding the neuropsychological status among individuals with acute HIV infection,
prior to antibody seroconversion.

Neuropathogenesis of HAND
There are a number of proposed mechanisms in regard to how HIV gains entry into the
CNS. These include translocation of infected monocytes and lymphocytes past the blood
brain barrier (BBB), transcytosis of free virus across neuroendothelial cells, or direct
infection of brain endothelial cells [9, 10]. HIV requires binding to the CD4 receptor and
a chemokine co-receptor (CCR5 or CXCR4). After entering the CNS, HIV mainly infects
macrophages and microglia cells given that they are the only cells in the brain that
express CD4 and CCR5. Infection of astrocytes expressing CXCR4, however, can also
occur [9].

The mechanisms of HIV-mediated neuropathology are multi-faceted. They involve direct
neurotoxic effects of the virus and viral proteins [9, 10]. In addition to producing these
viral products, infected macrophages and microglia also release inflammatory cytokines
such as tumor necrosis factor (TNF), interleukin-1 beta (IL-1 β), and interferon-gamma
(IFN- γ) that increase BBB permeability and also lead to direct damage of neurons and
glia [10]. Production of cellular products such as matrix metalloproteinases (MMPs) by

3
activated macrophages aid in the disruption of the BBB, leading to increased trafficking
of leukocytes into the CNS and subsequent neuroinflammation [11]. Chronic activation
of these inflammatory responses has been implicated in development of HIV-associated
cognitive dysfunction [12].

There is now evidence that CNS immunoactivation in present even in early HIV
infection. In a study of 96 antiretroviral naïve HIV+ individuals at a median 77 days after
estimated HIV exposure, it was found that these acute HIV subjects had elevations in
markers of CNS inflammation and macrophage/microglial activation that were similar to
that measured in chronically infected HIV subjects [13]. Given that these processes that
that lead to the neuronal damage and functional loss underlying HAND begin early in the
course of HIV infection, it is possible that initiation of ART in the acute stages of
infection can prevent development of HIC-associated neurocognitive impairment.

Negative Consequences of HAND
The most commonly described cognitive deficits in HIV infection occur in the domains
of motor and psychomotor function, executive function, processing speed, and attention
[14-16]. A meta-analysis of 41 neuropsychological (NP) studies evaluating cognitive
function as HIV disease progresses from asymptomatic to symptomatic to AIDS found
that domains with the greatest decline are motor function, executive function, and
information processing speed [16]. This has been consistent with other literature that has
noted cognitive impairment to worsen with disease progression [14]. Other domains
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known to be affected by HIV infection include verbal memory [17-19], and visual
memory and visuospatial function [16].

With the development of HAND, there are a number of adverse outcomes with respect to
everyday functioning. It has been shown that HIV-infected individuals with NP
impairment have nearly three times the rate of unemployment as unimpaired HIV+
individuals [20]. One study explored factors associated with difficulties returning to work
among HIV+ individuals and found that verbal memory deficits were the greatest barrier
to employment attainment [21]. NP impairment, specifically in the domains of memory
and executive functioning, has been shown to be related to lower antiretroviral therapy
adherence [22, 23]. Other major negative consequences of neurocognitive impairment in
the HIV population include decreased quality of life [24] and increased risk of mortality
[25]. In a prospective study of 414 HIV+ subjects over a median duration of
approximately 2.5 years, subjects with NP impairment were found to have nearly twice
the rate of death than unimpaired subjects [25]. Data regarding the specific causes of
death were not available in this study, but this increased rate of mortality remained
significant even after adjusting for other predictors of mortality such as older age, lower
CD4 counts, presence of AIDS-defining opportunistic infections, low hemoglobin, and
elevated serum ß2-microglobulin [25].

Causes of Persistent HAND
Different hypotheses have been proposed as possible causes for the persistence of HAND
in the era of ART. One explanation is poor CNS penetration of some antiretrovirals
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(ARVs) leading to ineffective treatment of CNS HIV disease [26]. Letendre et al.
constructed a schema to quantify the CNS Penetration Effectiveness (CPE) of
antiretroviral drugs. This construct was based on chemical properties of individual ARVs
such as molecular weight, pharmacokinetic data demonstrating measurable drug
concentration in human or animal cerebrospinal fluid (CSF), and clinical effectiveness
studies showing reduction in CSF viral load or improvement in cognition. Each ARV
drug was assigned a rank based on these qualities, and the rankings of individual drugs
were combined to give regimens a collective CPE rank score. Higher CPE ranks were
found to correlate with lower levels of CSF HIV viral load [26]. While other studies have
supported this finding of successful CSF viral suppression with more potent ARV
combinations [27], it is unclear whether such reduction in CSF viral translates to
improved neurocognitive outcomes. Some data has shown that ART regimens with
higher CNS penetration are associated with improved neurocognitive performance [28],
while others have shown that they lead to poorer neurocognitive performance [27]

Such studies showing an adverse effect of ARVs on cognition lend evidence to another
potential cause of persistent HAND: ART-mediated neurotoxicity in the CNS. There has
been well-documented data on the negative neuropsychiatric effects of Efavirenz,
predominately sleep disturbances, hallucinations, impaired memory and concentration,
and increased anxiety [29, 30]. Some work has also been done looking into the effects of
nucleoside reverse transcriptase inhibitors (NRTIs) on the CNS [31]. Using magnetic
resonance spectroscopy, investigators evaluated the concentration of N-acetylaspartate
(NAA, a marker of mitochondrial integrity) in the frontal white matter of HIV+
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individuals on didanosine and/or stavudine, HIV+ individuals on zidovudine and
lamivudine, HIV+ individuals on no antiretrovirals, and HIV-negative controls. They
found significantly lower NAA concentrations in the frontal white matter of HIV-infected
individuals on didanosine and/or stavudine when compared to HIV-negative controls, and
the two other HIV+ groups had intermediate NAA levels [31]. Additionally, longer
duration of didanosine and/or stavudine treatment and being on more than one NRTI
correlated with lower NAA frontal white matter concentrations. This study took into
account the severity and length of disease; so though HIV infection itself is associated
with decreases in NAA, these findings suggest that NRTIs might lead to additive damage
to CNS mitochondria and subsequent cognitive dysfunction [31].

A prospective study evaluating the effects of discontinuation of ART on cognitive
performance had an unexpected finding that raises more speculation about adverse
neurocognitive effects of ART [32]. In this study, HIV+ individuals who had been on a
number of different ART regimens for > 6 months discontinued ART at study entry and
completed neurocognitive function test at different time points over a 2 year period.
Surprisingly, neurocognitive performance improved significantly post-ART interruption
for the entire study duration, even after taken into consideration the presence of practice
effects. Additionally, individuals who restarted ART prior to the end of the study had no
significant change in cognitive functioning. It is plausible that these unexpected results
may have been due to ART-related neurotoxicity or other ART-induced neurocognitive
side effects that improved with treatment cessation [32].
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Another possible contributing factor to the persistence of HAND is the presence of viral
resistance. Poor individual adherence is a common culprit of drug resistance, leading to
the development of resistance-associated mutations. Some individuals might also be
infected with HIV strains that already contain mutations that decrease drug susceptibility.
An additional phenomenon that can arise is genetic compartmentalization of HIV-1
between the CNS and periphery, wherein the brain acts as a reservoir for the evolution of
unique HIV-1 variants. Previous studies demonstrated increased compartmentalization in
the CSF of individuals with chronic HIV infection (especially those with HAD), with
minimal to no compartmentalization in those with mild to no neurological disease [33,
34]. More recent work, however, has elucidated that compartmentalization can begin
earlier in the course of HIV disease during primary HIV infection, defined as the first
year after HIV transmission, even in the absence of any neurological symptoms [35].

Other factors that likely play a role in the continued presence of mild neurocognitive
impairment include incomplete HIV suppression while on ART. Data from a large
multicenter study group of over 1,500 HIV+ individuals found that 44% of those on ART
(482 of 1,105) had detectable plasma HIV viral load (>50 copies/mL) [5]. With such
sustained peripheral viral replication, there can be continued seeding of the brain leading
to persistent immune activation.

Even with treatment-controlled viral replication in the plasma, a phenomenon known as
CSF “viral escape” can occur—in which there is detectable CSF HIV RNA in the setting
of suppressed viremia in the blood [36-39]. This occurrence has been documented in
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HIV-infected individuals presenting with neurological symptoms [37-39]. One study has
demonstrated that this can occur in neurologically asymptomatic individuals as well [36].
In a cross-sectional study of 69 HIV+ subjects with no neurological symptoms and
undetectable plasma HIV RNA after >6 months of ART, investigators found that 10% of
these subjects exhibited CSF viral escape. Of note, the relative CNS penetrative rank of
the ART regimen was not found to predict CSF viral escape [36]. Most of these cases of
symptomatic CSF viral escape were found to harbor resistance mutations in the CSF
strains, and subsequent therapy adjustments based on these genotypes led to clinical
improvement [37-39].

Even with successful peripheral and central viral suppression, there has been evidence
that some level of immune activation continues [40-43]. In a study of 15 HIV+
individuals on ART for at least 4 years with HIV RNA levels <50 copies/mL in plasma
and CSF, investigators found that though markers of neuroinflammation (specifically
CSF neopterin, CSF WBC, and CSF immunoglobulin (IgG)) were lower than pre-ART,
neopterin and IgG production were still above the upper limit of normal in 60% of study
participants, indicating an ongoing intrathecal immunoactivation [41]. Theories that have
been proposed include continued low-grade viral replication in the brain or CSF that is
not detectable by current assays of CSF HIV RNA, transient CSF exposure to migrating
infected cells, or possibly a sustained level of cellular activation mediated by a nonspecific immune response [40-42].
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Efficacy of ART in Reducing HAND
The efficacy of ART in improving cognitive performance in individuals with advanced
HIV disease is well understood [28, 44-46]. The incidence of more severe neurocognitive
impairments such as HIV-associated dementia has greatly decreased since the advent of
ART [5, 47, 48]. Specific domains that have been shown to improve once on therapy
include concentration and psychomotor speed, fine motor function, and executive
function [49, 50]. On the other hand, verbal and visual memory, and visuospatial function
are domains that have not shown movement with ART [51].
However, studies demonstrate that a considerable proportion of chronically infected
persons continue to have neurocognitive deficits despite ART [52]. Importantly, studies
demonstrating chronic neurocognitive impairments despite treatment were focused on
individuals who started ART at variable durations since exposure. As such, it is possible
that neurological damage sustained during the early stages of HIV infection may have led
to NP impairments that were refractory to later treatment. Additionally, many of these
studies have not taken into account the CNS penetration of the drug regimens used and its
possible impact on the presence of continued neurocognitive deficits.

One study longitudinally examined the effect of ART on cognitive performance during
early infection [53], identifying mild deficits in NP performance pre-ART and
stabilization of cognitive function following ART. However, this observational study did
not control for practice effects and assessed participants about four months after
estimated HIV transmission, well after the acute phase of infection. Further, in previous
studies neurocognitive assessments were conducted at variable times after infection [53].
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We are aware of no published work that has examined the impact on NP testing of
starting ART very early after HIV identification during AHI.

Limited Research on Neurocognitive Status during Acute HIV Infection
It has been previously demonstrated that CSF HIV RNA can ben detected as early as
eight days post estimated date of transmission [54], with concurrent evidence of CNS
inflammation, measured by magnetic resonance spectroscopy imaging and CSF markers
of immune activation [13, 54]. There are limited data characterizing cognitive function in
primary HIV infection, and these studies have not included individuals captured during
the first month [55, 56]. Results from these studies have been mixed, with one study
reporting impairments in processing speed, executive function and learning among ARTnaïve patients with primary infection [53], while others have not demonstrated
statistically significant differences in neuropsychological (NP) performance between
primary infection participants and HIV-uninfected controls [57, 58]. No studies have
examined NP performance and its associations with HIV disease biomarkers during acute
HIV infection (AHI), prior to antibody seroconversion.

HIV/AIDS in Thailand
The first reported case of HIV/AIDS in Thailand occurred in 1984 [59]. When it was
shown that a key driver of the ensuing epidemic was commercial sex work, the country
implemented a successful nationwide HIV prevention campaign in the 1990s that was
focused on increasing condom use among sex workers and their clients [60, 61]. Funding
for HIV/AIDS in Thailand dramatically increased from just $684,000 in 1988 to $82
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million in 1997 [62]. And more importantly, while the majority of funds in the late 1980s
came from donors (e.g. in 1989, 90% of HIV funding was from international
development assistance programs), by 1997, the Royal Thai government financed
approximately 96% of the HIV/AIDS budget [62].

This impressive prevention campaign led to condom use in commercial sex
establishments increasing to over 90%; as a result, HIV prevalence in Thailand only
peaked to about 1.5% in 1996 [63]. Since then, there has been a steady decline in the
number of new HIV infections and people living with HIV in Thailand [64]. As of 2012,
HIV prevalence among adults in Thailand is approximately 1.1% with ~440,000 people
living with HIV, and ~21,000 deaths associated with AIDS [65]. The highest prevalence
rates are concentrated in high-risk populations, specifically sex workers, injection drug
users, and men who have sex with men [66].

Since 1992, impoverished HIV-positive Thai citizens had access to free antiretrovirals
[63]. And in 2001, the government integrated a universal antiretroviral treatment program
into its universal health coverage [67]. ART is now accessible at 95% of the 1,066 Thai
hospitals that provide HIV care [68]. Thailand has also started producing generic
antiretrovirals to further decrease the cost of treatment [63].

In 2012, the Thai government’s policy for initiating ART was based on an eligibility
threshold of CD4 count of 350 cells/mm3 or less [64]. The WHO revised its
recommendations on CD4 cell count threshold for ART initiation in 2013 and increased
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from 350 cells/mm3 to 500 cells/mm3 or less [69]. At this time, however, Thailand
decided to expand treatment eligibility even more and instituted policies in October 2014
that extended ART access to all HIV+ individuals regardless of CD4 count [64]. Based
on a CD4 cell count threshold of 350, data on access to HIV treatment in Thailand
showed that approximately 80% of eligible individuals are receiving ART [64].

Thailand has created a number of domestic and international HIV/AIDS research
collaborations. One such partnership is SEARCH, which was the site of this thesis
project. SEARCH is a research partnership initially established in 2005 among three
partners: the Thai Red Cross AIDS Research Centre (TRCARC), the University of
Hawaii (UH), and the Armed Forces Research Institute of Medical Sciences (AFRIMS, a
US army laboratory in Bangkok). SEARCH initiated a unique neurological study of
individuals identified during acute HIV to identify and characterize the earliest
immunological and virological events in the CNS beginning as early as the first week
post HIV exposure. Among its several aims, this study in particular also looks to
determine if early ART initiation during acute HIV impacts CNS complications during
chronic HIV. Study participants were recruited from the Thai Red Cross Anonymous
Clinic in Bangkok. Participants were identified and consented to HIV screening when
getting STD testing at the Red Cross. This thesis project investigated the presence of NP
impairment in acute HIV and the effects of early ART in longitudinal NP assessment.
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STATEMENT OF PURPOSE AND HYPOTHESES
The current study evaluated Thai participants who were identified within days of
estimated HIV exposure and before antibody seroconversion. We examined
neuropsychological performance at two time points (3 months and 6 months) following
ART initiation, and compared change in NP performance in the AHI cohort with that of
Thai normative controls to account for practice effects.

The two primary aims of this study are:
1) To investigate the presence of neuropsychological (NP) testing impairment in
participants with acute HIV infection and characterize baseline predictors of NP
performance in this population.
Hypothesis: NP testing impairment will be detected in acute HIV infection and
will correlate with baseline clinical biomarkers.

2) To evaluate whether immediate treatment with ART leads to improvement in NP
performance in follow-up. Baseline performance in ART naïve participants will be
compared to performance at 6 months of follow-up after ART.
Hypothesis: NP performance will improve above and beyond practice effects
following ART initiation.
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METHODS
Study design and participants:
Acute HIV study participants were recruited from the Thai Red Cross Anonymous Clinic
in Bangkok, Thailand. AHI participants were identified through nucleic acid testing, and
were characterized according to Fiebig stage defined by the sequential appearance of
viral RNA, antigen, and antibodies, as previously described [70, 71]. The inclusion
criteria for the AHI group were: confirmed acute HIV-1 infection, age >18 years, ARTnaïve, informed consent, and assent to initiating protocol-defined ART. Because the key
defining feature of the unique study population was laboratory-defined AHI, we did not
exclude any individuals eligible by the above criteria. However, mental health, substance
use and educational histories were obtained in all individuals, and no participants
included in the analysis had major psychiatric diagnoses.

Participants completed baseline clinical, neurological, CSF sampling (n=21/36), and NP
testing prior to starting ART. Due to the nature of the parent study, individuals were
randomized either to standard ART (efavirenz, tenofovir, and emtricitabine or
lamivudine) or standard ART plus raltegravir and maraviroc (MVC). There were no
significant differences in baseline characteristics (age, gender, days post HIV
transmission, CD4 count, CD8 count, plasma HIV RNA, and CSF HIV RNA) between
the two treatment arms using Mann-Whitney U test. Thus for the purpose of this study,
all participants were aggregated into one treatment group for analyses and the effect of
MVC was evaluated in multivariable models. All were followed longitudinally with NP
testing at 3 and 6 months after initial assessment.
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Clinical Characterization:
Psychiatric assessment: Participants completed the Thai version of the Hospital Anxiety
and Depression Scale (HADS), a 14-item scale with anxiety and depression subscales (7
items per subscale). Each item is scored from 0-3, with a total score range of 0-21 per
subscale. HADS scores were correlated with baseline NP scores using Spearman
correlation. Scores greater than 11 were considered positive cases. Illicit Drug Use
Quantification: Identification, duration, and frequency of drug use was elicited from
participants through structured interviews. Time of HIV transmission: AHI was
confirmed by serial laboratory testing at 2, 4, 8, 12, 24 weeks after initial detection of
positive HIV nucleic acid and negative HIV antibody. HIV transmission dates were
estimated from the dates of HIV exposure within the past 30 days reported by
participants. When multiple possible dates were given, the mean time point was selected.

Neuropsychological Testing:
The 4-test NP battery evaluated fine motor function/manual dexterity (Grooved Pegboard
test, non-dominant hand), psychomotor speed (Color Trails 1, Trail Making A), and
executive function/set shifting (Color Trails 2).

We utilized an existing normative NP testing database of HIV-uninfected Thai control
participants (n= 449) [72]. For the purpose of this study, we utilized only the 251 HIVuninfected controls in the similar age range as our AHI participants. The normative
sample had a median (IQR) age of 34 (27-42) years; 46% (n=115) were male and 30%
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(n=76) had a bachelor’s degree or higher. These control participants completed NP
assessments at baseline and at 6 months follow up. For baseline NP performance
analysis, data of all 251 HIV-uninfected controls were used. In longitudinal NP
performance analyses, only the 45 controls that had complete NP data for the six-month
study period were utilized.

The raw NP scores of AHI participants were standardized using data from the HIVuninfected control participants from equivalent age and education stratum to calculate zscores. A composite score (NPZ-4), the arithmetic mean of individual z-scores, was
calculated to provide an overall measure on NP performance.

Laboratory Measures:
CSF protein and cell count were measured via lumbar puncture. CSF and plasma HIV
RNA quantification (viral load) was completed using the Roche Amplicor HIV-1
Monitor Test V1.5 in most participants, but by Roche COBAS TaqMan HIV-1 Test V2.0
for 3 participants due to testing platform change during the parent study. The lower limit
of detection in CSF was 100 copies/ml due to dilution correction. CD4 and CD8 cell
counts were determined by flow cytometry.

Statistical Analysis:
Relationships between baseline demographic and clinical data and baseline NP
performance were examined by Spearman correlation. A multivariable regression model
was used to identify associations between clinical and laboratory parameters and NP
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performance at baseline (dependent variable = NPZ-4, independent variables = CD4, CSF
HIV RNA, days post transmission). Data that were found to not be normally distributed
were analyzed using the appropriate non-parametric tests. The non-parametric repeated
measures ANOVA, the Friedman test, was employed to compare baseline to follow up
NP values at the 3 and 6 month time point after treatment. The Mann Whiney U test was
utilized to compare the change in longitudinal NP performance of the AHI group to that
of the matched controls at the 6-month time point.

Study concept and design, participant recruitment, and acquisition of data were
performed by others. The student was involved solely in the analysis and interpretation of
data.

RESULTS
Baseline Characteristics of AHI Participants
We enrolled 36 AHI participants with a median (IQR) age of 28 (24-33) years (Table 1).
Most were young, educated men (89% male, 58% with bachelor’s degree or higher). The
median estimated days since HIV exposure was 19 days (interquartile range 15-24 days).
Over half (64%) were classified as Fiebig stage I (HIV RNA+, p24 antigen-, HIV IgM-)
and II (HIV RNA+, p24 antigen+, HIV IgM-). Most (86%) were infected with circulating
recombinant form (CRF) 01_AE, the predominant subtype in Thailand, with the
remaining being recombinant CRF01_AE and clade B. HIV-1 tropism data were
available for 34 participants; all were R5-tropic. The median (interquartile range) CD4
and CD8 counts were 411 (338-568) cell/mm3 and 578 (399-1013) cells/mm3,
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respectively. Plasma and CSF HIV RNA was 5.52 (4.56-5.87) log10 copies/ml and 3.37
(2.19-4.35) log10 copies/ml, respectively. Almost three-quarters (72%) denied lifetime
drug use or drug use in the four months prior to enrollment.

*Fiebig I: HIV RNA+; Fiebig II: HIV RNA+, p24 antigen +. **Denies any lifetime drug use or any drug
use in 4 months prior to enrollment

Baseline NP Performance and Correlates
The mean z-scores were close to zero for
each

NP

test

supportive

of

normal

performance compared to controls (Figure
1).

Specifically, the mean z-scores on

Grooved Pegboard, Color Trails 1, Color
Trails 2 and Trail Making A were -0.17, 0.20, -0.13, and -0.26, respectively. Mean
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NPZ4 was -0.19. However, eight participants performed greater than one standard
deviation below the mean performance of matched participants on at least two NP tests.
A subset met threshold criteria for anxiety (n=16, 44%), or depression (n=8, 22%) on the
HADS scale. The composite NP score, NPZ-4, did not correlate to depression (p=0.336)
or anxiety scores (p=0.861).

The baseline NP performance inversely correlated with CSF HIV RNA (r=0.493,p=0.023) and estimated days post transmission (r=-0.389, p=0.019) (Figure 2).

NPZ-4 vs. CSF VL

NPZ-4 vs. Days post transmission
2

NPZ-4

NPZ-4

2

0

-2

0

-2

0

2

4

CSF VL (log10 copies/ml)

6

0

10

20

30

40

50

Days post transmission

Figure 2. Baseline Correlations. Blue dot = Fiebig I/II (HIV RNA+, HIV IgM-), Orange dot = Fiebig
III/IV (HIV IgM+, HIV IgG-). NP performance was negatively correlated with cerebrospinal fluid (CSF)
viral load (VL) (r=-0.493,p=0.023) and days post-transmission (r=-0.389, p=0.019). NPZ4 scores did not
correlate with depression (p=0.336) or anxiety measures (p=0.861).

There was no significant correlation seen with NP performance and plasma HIV RNA
(p=0.203), CD4 count (p=0.440), CD8 count (p=0.468), CSF WBC (p=0.073), or CSF
protein (p=0.995). However, in multivariable modeling CSF HIV RNA, CD4 count and

20
estimated duration of infection were found to explain 31% of the variance in NP
performance (adjusted R-square = 0.310, p= 0.025) with individual effects significant for
CSF HIV RNA (β=-0.725, p=0.013) and CD4 (β=-0.882, p =0.004). Given the
unexpected inverse relationship between CD4 count and NP performance, we included a
CSF HIV RNA—CD4 count interaction term, which was significant (β=0.663, p<0.001)
and resulted in an increase in the explained variance of the full model to 72%. The 21
participants with LP were separated into 3 equal groups of high, moderate, and low CD4
count with ranges of 132-338 cells/mm3, 339-555 cells/mm3, and 565-970 cells/mm3,
respectively. As CD4 count increased, the strength of the correlation between CSF HIV
RNA and NPZ-4 decreased (low CD4 group, R2 = 0.37; moderate CD4 group, R2 = 0.16;
high CD4 group, R2 = 0.02).

Analysis of demographic differences between the subgroup of AHI participants (n=8)
that displayed NP testing impairment at baseline and the rest of the AHI participants
(n=28) revealed that the impaired subgroup had significantly higher levels of CSF HIV
RNA (U = 16, p = 0.047) than the non-impaired AHI participants (available CSF HIV
RNA in impaired group (n=5/8) vs. rest of AHI group (n=16/28)).

Longitudinal NP Performance
Thirty-one of the thirty six participants completed NP testing at both the three month and
six month follow-up period. There were no baseline characteristics differences between
participants retained and those lost to follow up using Mann-Whitney U test. We noted
no change in motor performance over 6 months, n=31 (χ2(2) = 1.613, p=0.446). However,
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there was a significant improvement noted in Color Trails 1, χ2(2) = 20.387, p=0.000
Trail Making A, χ2(2) = 8.581, p=0.014) and Color Trails 2, χ2(2) = 9.484, p=0.009) over
the 6 month period. Post-hoc analysis with Wilcoxon signed-ranks tests identified
significant improvement only in the initial 3 months following initial assessment (ps
<0.01) with no significant change in performance during the last 3 months, Figure 3.

Figure 3. Significant improvement was seen in week 0 to week 12 in processing speed (Color Trials 1, p =
0.000; Trail Making A, p = 0.008) and executive functioning (Color Trails 2, p=0.005) in the total cohort.
No change in motor performance.

In the 8 participants who initially performed greater than one standard deviation below
the mean of their matched controls on two or more NP tests, NP performance did not
significantly change at either the 3 or 6 month time point in any domain ((Color Trails 1,
χ2(2) = 5.250, p=0.072; Color Trails 2, χ2(2) = 4.750, p=0.093; Trail Making A, χ2(2) =
1.750, p=0.417; Grooved Pegboard, χ2(2) = 1.750, p=0.417)).
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In order to determine how much of the improvement in the AHI group could be due to
practice effects, we compared the change in longitudinal performance of the AHI group
(n=31) to that of the matched controls. Of the initial 251 HIV-uninfected controls used
for baseline NP performance analysis, 45 control participants had complete NP data for
the six-month study duration and were used for the longitudinal NP performance
analysis. This 45-participant subgroup had a median (IQR) age of 36 (25-45) years; 51%
(n=23) were male and 13% (n=6) had a bachelor’s degree or higher. In comparison, the
AHI group followed over time (n=31) was younger (median (IQR) age of 29 (23-33)
years), predominately male (90%, n=28), and more educated (52% (n=16) with
bachelor’s degree or higher).

We found that the degree of NP improvement in the AHI group was greater than that seen
in matched controls in one processing speed test, CT1 (U = 473, p = 0.018), Figure 4.
The observed improvement in the AHI group was similar to that of controls on the other
3 NP tests (CT 2, U = 516, p = 0.055; TM A, U = 612, p = 0.366; GP, U = 654, p =
0.646).

In multivariable modeling (dependent variable = change in performance in each NP test,
independent variables = MVC, CD4, CSF HIV RNA, days post transmission), MVC was
not found to be a significant predictor of longitudinal NP performance in any NP test
(CT1: β=-0.129, p=0.652; CT2: β=-0.042, p=0.876; GP: β=0.129, p=0.642; TM: β=0.418, p=0.069).
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Figure 4. When compared to HIV-uninfected controls in NP performance at 6 months, AHI participants
only had a greater improvement in one processing test (Color Trails 1, p = 0.018).

DISCUSSION
This prospective longitudinal study characterized NP performance in Thai participants
during AHI, beginning a median estimated 19 days since history of HIV exposure and up
to six months after ART. The performance of the AHI group did not significantly differ
from that of an age and education matched group of HIV-uninfected controls in the
domains of psychomotor speed, executive function, and fine motor performance.
However, a subgroup of individuals exhibited cognitive impairment at baseline that
correlated with higher CSF HIV RNA.
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There are several possible explanations for the relatively normal performance of most
AHI participants at baseline. First, given the very early timing following estimated
exposure, participants may have been at too early of a stage to have incurred processes
such as neuronal injury that would underlie any NP impairment. Neuronal injury can be
measured by CSF neurofilament light chain (NFL); and it has been shown that ARTnaïve HIV participants have normal CSF NFL levels and no evidence of axonal injury
during very acute HIV infection [73]. Taking into consideration the finding of a notable
subset of participants (~25%) that demonstrated baseline neurocognitive impairment, it is
most likely that there is a high level of heterogeneity in baseline NP performance in AHI
with some performing above average and others exhibiting significant impairment.

Secondly, small sample size could have limited our ability to identify very small
differences in NP performance. And lastly, it is possible that our neuropsychological
battery was too brief to have sufficient sensitivity in identifying HIV-related
neurocognitive impairment in acute HIV. Though some studies have successfully
identified neurocognitive impairment with a short battery [44], these brief batteries may
be more useful in chronic HIV rather than acute HIV.

Factors such as drug use, anxiety, and depression can impact NP performance [74-76]. It
is difficult to ascertain how much of an effect prior drug use and psychiatric symptoms
has on neurocognitive performance, but the relatively low incidence of reported illicit
drug use (72% reported no lifetime drug use or drug use in the 4 months prior to
enrollment) and the lack of correlation between anxiety/depressive symptoms and NP
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scores in this cohort reduces concern regarding the confounding nature of these
premorbid factors.

We investigated clinical and biological markers that might put AHI participants at a
higher risk for cognitive impairment. NP performance inversely correlated to CSF HIV
RNA and estimated days post HIV transmission, supporting the concept that NP
impairment might be, in part, related to the level of viral burden in the CNS during this
period. This was further supported by comparison analysis between the small subgroup of
AHI participants that displayed cognitive impairment at baseline and the rest of the AHI
participants, which demonstrated that those with baseline impairment had significantly
higher levels of CSF HIV RNA than their fellow AHI counterparts.

Interestingly, there was no significant association between CD4 count and NP
performance in univariate modeling in this cohort. Previous work has shown that low
CD4 count, especially a low CD4 nadir, is associated with neurocognitive impairment,
and that higher CD4 counts confer a lower risk of impairment [77, 78]. Our findings
might be explained by differential effects of the CD4 count in acute versus chronic HIV
infection. Unlike in chronic infection, low CD4 counts during AHI are less of a marker of
sustained immunosuppression and infection associated with neurocognitive damage, but
instead reflect acute and potentially variable immunologic responses with unclear
significance for the CNS.
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Although we did not identify an association between CD4 count and NP performance in
univariate analysis, a significant relationship was found in multivariable modeling
between these two factors. In addition to CD4 count, CSF HIV RNA and days posttransmission were also significant predictors of NP performance in a multivariable
regression model. As expected, CSF HIV RNA and days post transmission had an inverse
relationship with cognitive performance. However, there was an unexpected inverse
relationship between CD4 count and NP performance on regression analysis. Because
CD4 count drops and plasma viral load increases during the initial weeks of HIV
infection [79], it was hypothesized that higher CD4 would be associated with better NP
performance. Our finding is most likely related to the fact that CSF HIV RNA and CD4
are closely related, in fact, our correlational analysis showed a significant negative
correlation of r = -0.63 between these two factors thus suggesting multicollinearity and
distortion of the relationship between CD4 and NP performance.

We found that CD4 level moderated the negative relationship between CSF HIV RNA
and NP performance, suggesting that CD4 count may play a protective role in
maintaining neurocognitive function despite high levels of CSF HIV RNA. This finding
is important because it suggests that utilization of CD4 count alone as a clinical guidepost
to facilitate treatment decisions to address neurocognitive performance may not be ideal.
Further, preventing advanced immune suppression and initiating ART at higher CD4
counts may result in better overall cognitive outcomes among HIV-infected individuals.
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Following immediate ART initiation, we observed improvement in most tests during the
first 3 months, but change in only one test (CT 1) at 6 months exceeded that of change
observed in controls, supportive of practice effects. This contrasts with some reports that
have demonstrated deleterious effect of ART on cognition [27, 32]. The few participants
(n=8) who demonstrated NP impairment at baseline did not improve at 6 months. They
had higher levels of CSF HIV RNA at baseline, which could support early unresolved
cognitive deficits over 6 months, but it is noteworthy that only two of the eight
individuals reported recent illicit drug use. As such, premorbid substance abuse is not a
key driver of poor neuropsychological outcome after ART among individuals with
impaired performance at baseline.

Psychomotor performance and processing speed are regarded as more reliable markers of
cognitive impairment longitudinally, given that they are less influenced by practice
effects [53]. In our cohort, there were no deficits detected on these tests at baseline.
Given that our cohort was in the very early stages of HIV infection, the lack of deficit in
motor performance is not surprising. It has been documented that impairment in this
domain usually becomes evident in more advanced disease [16]. The use of culturally
matched longitudinal control data is a strength of our study; but, since our study group
was Thai and mostly infected with clade AE virus, broad generalizability may be limited.

In sum, we identify limited abnormalities on neuropsychological tests in AHI at baseline
with improvement following treatment.

We also identify about one-quarter of

participants having performance in an impaired range during AHI with limited

28
improvement after 6 months of ART. This study and future research should compare the
long-term NP performance trajectory from AHI to chronic disease compared to those
who initiate treatment later in disease. Such comparison may provide conclusive evidence
to support the need for earlier initiation of ART in order to prevent risk of developing
HIV-associated neurocognitive impairment.
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